Editas Medicine’s (EDIT) CEO Katrine Bosley on Q2 2017 Results – Earnings Call Transcript – Seeking Alpha
Sports Perspectives |
Editas Medicine's (EDIT) CEO Katrine Bosley on Q2 2017 Results – Earnings Call Transcript
Seeking Alpha Cpf1 is a new CRISPR genome-editing system that substantially expands the range of genomic sites we can target, and it may also have advantages in terms of specificity, manufacturing and delivery. In addition, Cpf1 may enable us to achieve more … Editas Medicine Announces Second Quarter 2017 Results and Update Editas Medicine, Inc. (NASDAQ:EDIT) Stock Closed 15.5% Above Its 50 Day Moving Average |
